Researchers demonstrated that genetically ablating both receptors for prostaglandin E2 (PGE2) in CAR‑T cells markedly enhances their potency against solid tumors in preclinical models. By removing PGE2‑mediated immunosuppression, engineered T cells showed improved infiltration, persistence, and tumor killing in laboratory studies. The work, reported by an academic team, identifies PGE2 signaling as a modifiable suppressive axis in the tumor microenvironment and suggests a scalable gene‑editing strategy to boost CAR‑T efficacy outside hematologic malignancies. The approach uses targeted knockout of both receptors to blunt a dominant local suppressive signal rather than systemic pharmacologic blockade. Translational steps will include safety profiling of double receptor knockouts and manufacturing considerations, but the data advance a promising avenue for solid‑tumor cell therapy engineering.